Candel Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
(a)None.
(b) The following table describes contracts, instructions or written plans for the sale or purchase of our securities adopted by our directors and certain officers during the fourth quarter of 2024, each of which is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c), referred to as Rule 10b5-1 trading plans.
| Name | Action Taken | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|
| Paul Peter Tak, M.D., Ph.D., FMedSci (Chief Executive Officer, President and Director) | Adoption (November 19, 2024) | Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) | Earlier of (i) 466 days and (ii) the completed sale of the maximum aggregate number of securities under the plan | Up to 868,783 shares |
| Charles Schoch (Interim Chief Financial Officer, Treasurer and Secretary) | Adoption (November 15, 2024) | Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) | Earlier of (i) 379 days and (ii) the completed sale of the maximum aggregate number of securities under the plan | Up to 20,000 shares |
| Francesca Barone, M.D., Ph.D. (Chief Scientific Officer) | Adoption (November 22, 2024) | Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) | Earlier of (i) 372 days and (ii) the completed sale of the maximum aggregate number of securities under the plan | Up to 38,646 shares |
| W. Garrett Nichols, M.D., M.S. (Chief Medical Officer) | Adoption (November 22, 2024) | Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) | Earlier of (i) 372 days and (ii) the completed sale of the maximum aggregate number of securities under the plan | Up to 49,848 shares |
| Seshu Tyagarajan, Ph.D. RAC (Chief Technical Development Director) | Adoption (November 15, 2024) | Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) | Earlier of (i) 470 days and (ii) the completed sale of the maximum aggregate number of securities under the plan | Up to 61,278 shares |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.